Intervacc is trading at €0.06, down -17.16%, with no confirmed company-specific catalyst identified.

  • No company-specific announcement, earnings release, regulatory action, or transaction was identified for September 17–18, 2026.
  • The decline is not supported by available sector context, where biotechnology stocks rose; it may reflect stock-specific trading, liquidity, or delayed disclosure.
  • Intervacc’s healthcare-conference presentation, dated September 15, does not directly explain the September 18 decline.